Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidin… Read more
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Resilience Ratio
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has an Asset Resilience Ratio of 12.64% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥215.76 Million | 12.64% |
| Total Liquid Assets | CN¥215.76 Million | 12.64% |
Asset Resilience Insights
- Moderate Liquidity: Xinxiang Tuoxin Pharmaceutical Co.Ltd. has 12.64% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Xinxiang Tuoxin Pharmaceutical Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.27% | CN¥250.88 Million | CN¥1.76 Billion | +3.90pp |
| 2023-12-31 | 10.37% | CN¥190.70 Million | CN¥1.84 Billion | -2.66pp |
| 2022-12-31 | 13.03% | CN¥240.16 Million | CN¥1.84 Billion | -2.80pp |
| 2021-12-31 | 15.83% | CN¥220.62 Million | CN¥1.39 Billion | -- |